Diagnostics News and Research

RSS

Enzo Biochem to unveil data on AmpiProbe HCV assay at ESCMID meeting

Enzo Biochem Inc. announced today that the company will present for the first time peer-reviewed data on detection of hepatitis C virus (HCV) using its novel AmpiProbe technology platform, which provides low cost and high sensitivity real-time nucleic acid amplification assays.

9 Mar 2012

FDA clears Abbott's FreeStyle InsuLinx Blood Glucose Monitoring System

Abbott today announced that it has received U.S. Food and Drug Administration (FDA) clearance for the FreeStyle InsuLinx Blood Glucose Monitoring System, the first from Abbott to include a touch-screen interface, automated logbook and several personalization features designed to improve the diabetes management experience for patients.

8 Mar 2012

Transgenomic fourth quarter total revenue increases 68% to $8.6M

Transgenomic, Inc. today reported financial results for the year ended December 31, 2011 and provided a business update.

7 Mar 2012

Illumina launches new highly multiplexed cancer panel

Illumina today introduced the TruSeq Amplicon - Cancer Panel, a highly multiplexed panel that will allow researchers to accurately sequence hundreds of the most relevant cancer loci, even in difficult samples such as formalin-fixed, paraffin embedded (FFPE) tumor samples.

From Illumina, Inc. 7 Mar 2012

e-Health records don't always equal reduced costs

A study published in Health Affairs found that electronic health records don't necessary lead to reducing health care spending or fewer diagnostic tests.

7 Mar 2012

Medidata net revenues increase 11% to $184.5M for full year 2011

Medidata Solutions, a leading global provider of SaaS clinical technology solutions that enhance the efficiency of clinical development, today announced its financial results for the fourth quarter and full year 2011, and provided detailed financial guidance for the first quarter and full year 2012.

6 Mar 2012

New AD marker can predict mental decline

A new marker of Alzheimer's disease can predict how rapidly a patient's memory and other mental abilities will decline after the disorder is diagnosed, researchers at Washington University School of Medicine in St. Louis have found.

6 Mar 2012

Penn-led team develops universal approach to personalized cancer therapy based on T cells

Researchers from the Perelman School of Medicine at the University of Pennsylvania report this month in Cancer Research a universal approach to personalized cancer therapy based on T cells. It is the first time a system for making an adaptable, engineered T-cell to attack specific tumor types has been proposed, depending on which abnormal proteins, called antigens, are expressed by individual patients' tumor cells.

6 Mar 2012

New DNA-reading technology could lead to correct genetic diagnosis for muscle-wasting diseases

Scientists at The University of Nottingham have used a revolutionary new DNA-reading technology for a research project that could lead to correct genetic diagnosis for muscle-wasting diseases.

6 Mar 2012

Abbott, GenLab collaborate to develop new assay for PLEX-ID automated microbial identification system

Abbott announced today it will collaborate with Genetics Laboratory, Inc. on the development of a molecular diagnostic test that will be designed to rapidly detect microorganisms that cause orthopedic infections.

5 Mar 2012

Tobii introduces next-generation eye tracking integration component at CeBIT

Tobii Technology, the world leader in eye tracking and gaze interaction, today announced the introduction of its next-generation eye tracking integration component, the Tobii IS-2 Eye Tracker.

5 Mar 2012

Berg Diagnostics achieves CLIA certificate of accreditation

Berg Diagnostics, a Boston-based molecular diagnostics company has received Massachusetts Clinical Laboratory Licensure and Certificate of Registration from the Centers for Medicare and Medicaid Services under the Clinical Laboratory Improvement Amendment (CLIA).

2 Mar 2012

KF's TBI research director to speak at Washington conference

Jordan Grafman, PhD, director of Traumatic Brain Injury Research at Kessler Foundation, is an invited speaker at The 2nd Annual Traumatic Brain Injury Conference on March 6, 2012, in Washington, DC. Dr. Grafman will describe the long-term cognitive and social consequences of traumatic brain injury.

1 Mar 2012

Positive results from Critical Diagnostics' biomarker study in ambulatory heart failure patients

Critical Diagnostics, a biomarker company focused on cardiovascular diseases, today announced positive results from a multi-center study in ambulatory heart failure patients, which confirmed that a contemporary panel of biomarkers, including ST2, was strongly predictive of risk and significantly improved the likelihood of identifying patients at risk for adverse events, compared to the most commonly used clinical risk score in heart failure, the Seattle Heart Failure Model.

29 Feb 2012

IDWeek 2012 to take place October 17-21 in San Diego

Abstracts are now being accepted for IDWeek 2012, the first-ever combined meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS).

29 Feb 2012

FDA clears Meridian Bioscience's TRU Legionella test

Meridian Bioscience, Inc. today announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for TRU Legionella, a new rapid assay for detection of legionellosis.

28 Feb 2012

GE Healthcare Discovery MR750w 3.0T scanner installed at BRMI

Patients and clinicians alike are celebrating the newest arrival at BRMI@ Dyker Heights of an innovative GE Healthcare Discovery MR750w 3.0T scanner.

27 Feb 2012

Biodesix, Kadmon enter Phase 3 non-small cell lung cancer study collaboration

Biodesix Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix' VeriStrat® test in a Phase 3 non-small cell lung cancer (NSCLC) study of Kadmon's KD019, a reversible tyrosine kinase inhibitor (TKI) targeting EGFR, HER2, VEGFR2 & 3, and SRC.

27 Feb 2012

AB SCIEX granted ISO 13485 certification for quality management system.

AB SCIEX, a global leader in life science analytical technologies, today announced that it has achieved ISO 13485 certification for its quality management system. ISO 13485 is an international standard that requires a manufacturer to demonstrate a comprehensive and compliant quality management system suitable for the design and manufacturing of medical devices.

27 Feb 2012

FDA grants 510(k) clearance for Ventana Ki-67 image analysis algorithm

Ventana Medical Systems, Inc., a member of the Roche Group, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VENTANA Companion Algorithm Ki-67 (30-9) image analysis application used with the VENTANA iScan Coreo Au scanner running VIRTUOSO software.

27 Feb 2012